PepSets™ Peptide Libraries ❭

PepSets™ can be supplied with a precise length and offset designed to best suit the user’s assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence to adapt the usage for any experimental purpose.

In recent years, PepSets™ have had tremendous successes in the immunology sector for vaccine and drug development. These versatile molecular tools have further applications in dozens of fields, including epitope mapping and structure-activity studies.  

  • Discover crucial residues with an Alanine Scan Library 
  • Map epitopes with an Overlapping Peptide Library 
  • Narrow down the shortest active sequences with a Truncated Peptide Library

Fast & Reliable

Mimotopes is the founder of peptide libraries. Across the 35 years since its inception, the technology and its userbase have developed side-by-side to make PepSets™ an unrivaled juggernaut in research today.

Hundreds of peptides are synthesized simultaneously with Mimotopes’ exclusive parallel synthesis technology. Thanks to a rapid production cycle, peptide libraries reach their users fast, aiming to never delay critical experiments.

Contact us today for a quote!

Australia

☎ +61 3 9565 1111
✉ australia@mimotopes.com

North and South America

☎ +1 651 603 0909
✉ useast@mimotopes.com
uswest@mimotopes.com

Asia

☎ +61 3 9565 1111
✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547
✉ europe@mimotopes.com

Go to article: Home | Why can’t the US figure out weight loss drug prices?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Precision Health Technologies Accelerator Company InsightGo to article: In DepthGo to article: Why can’t the US figure out weight loss drug prices?Go to article: Psychedelic drug developers redesign trials to avoid Lykos faux pasGo to article: Can pharma tariffs “Make America Manufacture Again”?Go to article: Policy changes and digital strategies guide oncology researchGo to article: The European Market Access Lag: 2021–2024Go to article: Vutrisiran marks first silencer approved for ATTR-CMGo to article: ASCO 2025: Key highlightsGo to article: SCHOTT Pharma Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Excellence Awards 2025: NovotechGo to article: Buyer's GuidesGo to article: Next issue